• Famoco

  Participated · Equity · Feb 2017

  Famoco is a Paris-based provider of Android-based transactional solutions led by co-founder and CEO Lionel Baraban. Its FX Series are remotely managed devices that combine smart card security with a secure version of Android, and the platform is compatible with selected Android devices such as Samsung tablets. The platform enables businesses to deploy and remotely manage business-critical applications across different device types. The company has deployed more than 100,000 devices in over 30 countries and works with international groups including Orange, Gemalto, Alipay, PayPal and AccorHotels. Famoco also maintains offices in Bruxelles, New Delhi and Hong Kong. It raised €11m to recruit new people, open offices across Europe, the Middle East, Africa, the USA and Asia, and expand adoption of its solutions.

• Opendatasoft

  Participated · Series A · Oct 2016

  Opendatasoft provides a SaaS data-democratization platform that lets internal teams rapidly build compelling digital experiences and share data across internal and external ecosystems. Led by CEO and co-founder Jean-Marc Lazard, the company positions its product to help customers transform operations and increase transparency with stakeholders. More than 300 organizations worldwide — including Schneider Electric, Groupe BPCE, Veolia, Enedis, Saint‑Gobain and major cities such as Paris and Vancouver — use the platform. The company plans to use the new funding to scale operations, accelerate international expansion and enter new vertical markets. It intends to strengthen its North American presence by expanding its Boston office and to boost activities in Australia and across Europe, targeting verticals such as retail, services and healthcare. OpenDataSoft builds a cloud-based data publishing and sharing platform that enables data visualization, API access, and reuse by citizens, startups, and internal teams. The platform offers advanced capabilities such as real-time data processing, targeting Smart City and IoT projects. The company serves over 80 customers across ten countries, including public bodies and large enterprises. Customers named in the article include the Portuguese Ministry of Health, the Swiss National Railway Company, the City and County of Durham (NC), the City of Paris, the French Ministry of Education, Veolia, and Saint-Gobain. OpenDataSoft was founded five years ago in Paris and is led by Co-Founder and CEO Jean-Marc Lazard. The company plans to strengthen R&D in France, open a North American headquarters in Boston, hire sales and marketing in North America, and expand into additional European markets such as Germany, Italy, Spain and the UK.

• Jabmo

  Participated · Equity · Dec 2015

  Jabmo is a leading vendor of industrial account-based marketing (ABM) solutions that provides account sensing and personalized account-based advertising. The platform captures anonymous buying behavior of target accounts and executes personal, relevant account-based advertising strategies. It integrates with Oracle Marketing Cloud, Salesforce Marketing Cloud, Marketo, and Microsoft Dynamics, and counts customers including Sealed Air, Schneider Electric, and Fives. Jabmo raised €10 million in funding led by Raise Ventures and Idinvest to accelerate international expansion and support product development. New product enhancements aim to increase firmographic data for target accounts and expand the company’s IP database to improve reach within accounts and enable segmentation by division or business unit, per CTO Rich Flati. The company has offices in France (HQ), Sweden, the United Kingdom, the United States, and Mauritius. Azalead builds an account-based marketing platform that surfaces the most promising potential clients by combining a database of millions of data points with a customer’s own CRM and email data. The product tracks website visitors (using IPs and cookies), helps build target lists from past CRM/email information, segments visitors, and customizes ad campaigns. It integrates with existing CRM and email services and can focus ad spend on key accounts rather than mass targeting. Customers in France include Microsoft, Europcar, and iAdvize. Azalead charges between $15,000 and $100,000 per year depending on data volume and ad scenarios. The company has expanded its product beyond basic visitor identification and in 2015 executed two funding rounds and hired 20 people. Reported near-term plans are to double the R&D team, grow the sales team, and explore a potential U.S. expansion in 2016, while adding more customization features such as A/B testing and industry-specific landing pages. Azalead Software is a Paris-based B2B marketing automation company founded in 2013 by Nick Heys and Hervé Paolini. The company leverages proprietary algorithms and pattern learning to identify, track and deliver display ads to business prospects. Its platform alerts sales representatives when key accounts are ready to engage and integrates with Salesforce.com and Microsoft Dynamics. The service is used by over 500 B2B companies to accelerate sales. Azalead raised €2m in funding in a round led by Aurinvest with participation from a group of angel entrepreneurs. The company intends to use the funds to accelerate growth of its platform.

• Smallable

  Participated · Equity · Jun 2015

  Launched in 2008 by Cécile Roederer and led by Grégoire de Tilly, Smallable.com is a Paris-based online fashion and design concept store for children aged 0-16. The site curates fashion, furniture, decoration, games and books from 400 brands at affordable prices. The company expects a turnover of €20m at the end of the year. Smallable.com raised €5m in its second funding round to support growth. Management says the funds will be used to expand abroad, improve the user experience and hire new people. The business combines e-commerce selection with a design-focused positioning in the children's market. Smallable is a retailer that focuses on designer rag dolls and eco-friendly puzzles for children. The company's assortment emphasizes design-led toys and sustainable puzzle products. TechCrunch covered a recent financing involving the business. That coverage highlights Smallable's combination of designer product styling and environmentally minded materials. The article frames the company within the children's toy and gift market. No operational metrics are reported in the piece.

• PathoQuest

  Participated · Equity · Jul 2013

  PathoQuest, a spin‑out of Institut Pasteur based in Paris, offers a metagenomics approach that combines an NGS platform, proprietary sample‑preparation and a pathogen genome database with an automated analysis pipeline for comprehensive pathogen detection. The company has developed iDTECT™ Blood, described as the first and only CE‑IVD metagenomic test for clinical infectious disease diagnosis. PathoQuest also provides Biologics Genomic Services to biopharmaceutical companies to help secure production of vaccines, recombinant proteins and cell and gene therapies. Those services are currently being utilized by a growing number of major biopharma and clinical‑stage biotech companies. PathoQuest closed an €8M financing series that includes a venture loan and investor financing plus €427K of non‑dilutive funding from the French PIA3 i‑Nov program. Management says the proceeds will further establish the company’s position in applying NGS to microbiologic testing, expand its Biologics Genomic Services business and advance iDTECT Blood in clinical settings. PathoQuest is a Paris-based molecular diagnostics company founded in 2010 as a spin-off of the Pasteur Institute and the ENVA (Ecole Nationale Veterinaire d’Alfort). Led by Prof. Marc Eloit (president and CSO) and CEO Luc Boblet, the company develops a next-generation sequencing (NGS) cloud-based diagnostic assay and a bioinformatics workflow designed to assist diagnostic decision-making for infectious diseases. The company announced it raised about $4.96M in the reported financing and had previously raised €2M in March 2011. PathoQuest intends to use the new funds to run the first clinical study of a new diagnostic assay targeting severe multi-etiological infectious episodes in immuno-compromised patients. It plans to extend the clinical trial into the U.S. in the coming months and aims to launch a first commercial product in 2015.

No current team members are available.